CA3191747A1 - Gut-selective sequestering agents for the treatment and prevention of autism and related disorders - Google Patents

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Info

Publication number
CA3191747A1
CA3191747A1 CA3191747A CA3191747A CA3191747A1 CA 3191747 A1 CA3191747 A1 CA 3191747A1 CA 3191747 A CA3191747 A CA 3191747A CA 3191747 A CA3191747 A CA 3191747A CA 3191747 A1 CA3191747 A1 CA 3191747A1
Authority
CA
Canada
Prior art keywords
sequestrant
intestinal
subject
mice
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3191747A
Other languages
English (en)
French (fr)
Inventor
Anthony Stewart Campbell
David H. Donabedian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapeutics Inc
Original Assignee
Axial Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapeutics Inc filed Critical Axial Therapeutics Inc
Publication of CA3191747A1 publication Critical patent/CA3191747A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3191747A 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders Pending CA3191747A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
CA3095724A CA3095724C (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3095724A Division CA3095724C (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (1)

Publication Number Publication Date
CA3191747A1 true CA3191747A1 (en) 2018-10-04

Family

ID=63677186

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3191747A Pending CA3191747A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
CA3095724A Active CA3095724C (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3095724A Active CA3095724C (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Country Status (9)

Country Link
US (4) US10617718B2 (https=)
EP (1) EP3600349A4 (https=)
JP (1) JP6978122B2 (https=)
KR (1) KR102328323B1 (https=)
CN (2) CN110944650B (https=)
AU (3) AU2018243836B9 (https=)
BR (1) BR112019020289A2 (https=)
CA (2) CA3191747A1 (https=)
WO (1) WO2018183986A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020289A2 (pt) 2017-03-31 2020-09-01 Axial Biotherapeutics, Inc. agentes sequestrantes seletivos do intestino para o tratamento ou prevenção de autismo e distúrbios relacionados
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
CA3164484A1 (en) * 2019-12-19 2021-06-24 Hill's Pet Nutrition, Inc. Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines using tomato pomace and methods of identifying canines at risk of such conditions
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体
CA2754203A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US10071089B2 (en) * 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
BR112019020289A2 (pt) 2017-03-31 2020-09-01 Axial Biotherapeutics, Inc. agentes sequestrantes seletivos do intestino para o tratamento ou prevenção de autismo e distúrbios relacionados

Also Published As

Publication number Publication date
CA3095724A1 (en) 2018-10-04
NZ758692A (en) 2022-03-25
WO2018183986A1 (en) 2018-10-04
CN114569633A (zh) 2022-06-03
BR112019020289A2 (pt) 2020-09-01
CN114569633B (zh) 2023-11-17
AU2018243836B9 (en) 2021-05-13
KR102328323B1 (ko) 2021-11-19
AU2022200220A1 (en) 2022-02-10
CN110944650B (zh) 2022-03-04
US20180303876A1 (en) 2018-10-25
JP2020513032A (ja) 2020-04-30
US10617718B2 (en) 2020-04-14
AU2018243836B2 (en) 2021-04-22
AU2021206871A1 (en) 2021-08-12
AU2018243836A1 (en) 2019-11-21
US20230364135A1 (en) 2023-11-16
CN110944650A (zh) 2020-03-31
AU2021206871B2 (en) 2021-10-14
EP3600349A1 (en) 2020-02-05
US11007219B2 (en) 2021-05-18
JP6978122B2 (ja) 2021-12-08
US20200368276A1 (en) 2020-11-26
US20200390809A1 (en) 2020-12-17
KR20200024133A (ko) 2020-03-06
CA3095724C (en) 2023-04-18
EP3600349A4 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
US20230364135A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP2022088641A (ja) 細菌株を含む組成物
Zhang et al. Research progress of microbiota-gut-brain axis in Parkinson's disease
KR20220016481A (ko) 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
JP2022517754A (ja) 菌株、組成物および使用方法
Nápoles-Medina et al. Oral administration of Lactobacillus inhibits the permeability of blood‐brain and gut barriers in a parkinsonism model
CN115003318A (zh) 包含细菌菌株的组合物
JP2020520928A (ja) 細菌株を含む組成物
KR20220034816A (ko) 박테리아 균주를 포함하는 조성물
Shi et al. Production, Mechanisms, and Therapeutic Strategies of Tryptophan Metabolites in CNS Diseases
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
Zhu et al. Microenvironment Self‐Adaptive Nanoarmor to Address Adhesion‐and Colonization‐Related Obstacles in Impaired Intestine Promote Bacteriotherapy Against Parkinson's Disease
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
Wang et al. Alternate-day fasting ameliorates α-synuclein pathology and suppresses inflammation via the gut-brain axis in an MPTP-induced subacute mouse model of Parkinson’s disease
He et al. W2006 Beneficial Effects of Fermented Milk Containing Lactobacillus GG and L. Gasseri Tmc0356 On Regulating Intestinal Microflora and Immune Responses for Patients with Allergic Disease
KR20220119055A (ko) 박테리아 균주를 포함하는 조성물
NZ785569A (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230525

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240822

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251117